Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 10, 2017. The document serves as a transaction notification regarding insider trading activities involving Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them (PCA), rather than a financial performance report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions:
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $39.43 per ADS.
- Transaction Date: January 9, 2017.
- Transaction Type: Notional allocation within the GSK 401(K) plan resulting from the revaluation of the cash element of the notional investment.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records two specific increases in ADS holdings:
- Dr. M M Slaoui (Chairman, Global Vaccines): Increase of 29 ADSs.
- Dr. K Slaoui (PCA of Dr. M M Slaoui): Increase of 10 ADSs.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of specific share movements.
Key Facts for Investor Verification
- Verify the total number of ADSs held by Dr. M M Slaoui and Dr. K Slaoui following these notional allocations.
- Confirm the market price of GSK ADSs on January 9, 2017, to validate the reported transaction price of $39.43.
- Note that these transactions were automatic notional allocations within a 401(K) plan, not discretionary open-market purchases.